“The superior overall survival demonstrated in DESTINY-Gastric04 confirms that ENHERTU could become the global standard of care in the second-line metastatic setting of HER2 positive gastric ...

Enhertu significantly improved overall survival and progression-free survival compared to Cyramza plus paclitaxel in HER2-positive metastatic GC/GEJ patients. The DESTINY-Gastric04 trial established ...

As such, "the combination of T-DXd and pertuzumab may represent a new first-line standard of care for patients with ...

AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...

Trastuzumab deruxtecan belongs to a group of antineoplastic drugs known as antibody-drug conjugates (ADCs). This type of ...

Researchers at ASCO's annual meeting also discussed the importance of repeat biopsies to assess HER2 status after first-line treatment.

AstraZeneca/Daiichi's Enhertu shows survival benefit vs standard care in HER2+ gastric cancer patients, with 14.7 vs 11.4 ...

Tumors with low- and ultra-low levels of a protein called HER2 are treatable with Enhertu, but harder to identify. New ...